Restylane Lyft Receives New Indication
November 5, 2018 – The U.S. FDA has approved a new indication for Restylane® Lyft (hyaluronic acid/lidocaine) gel, manufactured by Galderma, to provide cheek augmentation and correction of age-related midface contour deficiencies in patients over the age of 21.
Restylane Lyft uses a blunt-tip cannula – a thin tube for insertion into a body cavity – to deliver a dermal filler (hyaluronic acid) to a designated site. According to the manufacturer’s press release, the use of a cannula rather than a needle may minimize patient downtime and side effects such as bruising, swelling, and damage to blood vessels compared to treatments that require a needle injection. The product is also approved for use as a dermal filler in the nasolabial folds (laugh lines) and back of the hands.
Galderma’s Restylane line of dermal fillers also includes Restylane® Silk, the only other dermal filler approved for use with a cannula.